

Inclusion Criteria

- 6 months to 21 years
- Suspicion of acute musculoskeletal infection (Symptoms less than 2 weeks): osteomyelitis, septic arthritis, pyomyositis

Exclusion Criteria

- Infants (less than 6 months)
- Chronic and subacute musculoskeletal infection (Symptoms greater than 2 weeks)
- Postoperative infection
- Penetrating trauma
- Patient with hardware
- Myelomeningocele
- Chronic recurrent multifocal osteomyelitis (CRMO)
- Immunocompromised

¹ Suspicion of MSK Infection

Obtain the following:

History

Pain, fever, inability to bear weight, gait disturbance/limp, limited use or immobility of extremity or spine, travel to endemic Lyme areas

Physical Exam

Limited range of motion, swelling, tenderness, warmth at site, fever, erythema, psoas sign

² Aspiration Results

For reference only

- >50,000 WBC: Proceed to OR
- 25,000-50,000 WBC: Consider OR, close observation
- <25,000 WBC: Close observation and consider auto-immune and/or post-infectious diagnoses


³ Specimen Collection

Lab Order Prioritization of Joint Fluid Depends on Volume Obtained (4-5 mL)

1. Culture Fluid (Code:CUFLD)
2. Cell Count (Code:FLCT)
3. For patients ≤ 48 months order Kingella PCR from synovial fluid, tissue or bone (Code:KINPCR)
4. Lyme testing if clinically indicated. Order Lyme serology from blood (Code:BBPEPA) and Lyme PCR from synovial fluid Only (Code:LYMPER).

How to submit specimens: For all tests listed above except Lyme serology, use a needleless capped syringe or sterile container. For Lyme serology, use a serum separator (red top).

See the "PED IP MSK Infection Specimen Collection" order set for specific order information.



1 Medical Management

- Aggressive hydration (given risk of bacteremia/potentially nephrotoxic drugs)
- CBC and CRP 36-48H from surgical procedure or admission labs
- Additional labs every 48H PRN and on planned discharge day
- PICC lines not routinely recommended
- If MSSA or MRSA, there is increased DVT risk. Consider imaging with a Doppler Ultrasound if prolonged swelling or pain out of proportion to infection or exam.

2 Criteria to Transition to PO Antibiotics

Must meet ALL of the following criteria:

- No fever >24H
- Minimal pain
- CRP decreased by >50% of initial value
- Blood cultures negative for 36H
- No signs of endocarditis, pneumonia, or DVT

3 Continued Medical Management Criteria

- Fever >72H
- Persistent bacteremia (≥ 3 cultures)
- Worsening pain
- CRP not improving

4 Discharge Criteria

- Pain controlled by PO meds
- Tolerating PO antibiotics

5 Specimen Collection

Lab Order Prioritization of Joint Fluid Depends on Volume Obtained (4-5 mL)

1. Culture Fluid (Code:CUFLD)
2. Cell Count (Code:FLCT)
3. For patients ≤ 48 months order Kingella PCR from synovial fluid, tissue, or bone (Code:KINPCR)
4. Lyme testing if clinically indicated. Order Lyme serology from blood (Code:BBPEPA) and Lyme PCR from synovial fluid only (Code:LYMPCCR).

How to submit specimens: For all tests listed above except Lyme serology, use a needleless capped syringe or sterile container. For Lyme serology, use a serum separator (red top).

If tissue and/or bone is collected in the OR, submit in a sterile container and place orders for tissue culture (Code:CUTISS) and bone culture (Code:CUBONE).

See the "PED IP MSK Infection Specimen Collection" order set for specific order information.



IV Antibiotic Table				
Patient Demographic	Bacterial Targets	Drug	Dose	Max Single Dose
6 months - ≤4 years	<i>S. aureus</i> , <i>S. pyogenes</i> (GAS), <i>K. kingae</i>	Clindamycin AND	13mg/kg IV q8h	900mg
		Cefazolin	40mg/kg IV q8h	2000mg
6 months - ≤4 years and not fully immunized against <i>H. influenzae</i> or <i>S. pneumoniae</i>	<i>S. aureus</i> , <i>S. pyogenes</i> (GAS), <i>K. kingae</i> , <i>H. influenzae</i> , <i>S. pneumoniae</i>	Clindamycin AND	13mg/kg IV q8h	900mg
		Ceftriaxone	75mg/kg IV q24h	2000mg
> 6 months and ill appearing (Hemodynamic instability OR anticipated/existing need for intensive care)	<i>S. aureus</i> , <i>S. pyogenes</i> (GAS), <i>K. kingae</i> , <i>H. influenzae</i> , <i>S. pneumoniae</i>	Vancomycin ¹ AND	15mg/kg IV q6h	1000 mg
		Ceftriaxone	75mg/kg IV q24h	2000mg
		Consider Clindamycin ²	13mg/kg IV q8h	900mg
> 4 years old	<i>S. aureus</i> , <i>S. pyogenes</i> (GAS)	Clindamycin	13mg/kg IV q8h	900mg
		Consider Ceftriaxone ³	75mg/kg IV q24h	2000mg
<p>¹ Recommended vancomycin starting dose. Goal trough 10-15µg/mL. Pharmokinetic service will monitor trough levels and adjust accordingly.</p> <p>² Consider adding clindamycin empirically in critically ill patients while waiting for confirmation of therapeutic vancomycin level.</p> <p>³ If not fully immunized against <i>H. influenzae</i> or <i>S. pneumoniae</i> OR concern for Lyme disease or Gonorrhea, add ceftriaxone.</p>				

Suggested Antibiotics for PO Transition			
Bacterial Targets	Drug	Dose	Max Single Dose
MSSA or <i>K. kingae</i>	Cephalexin	40mg/kg/dose q8h	1000mg
MRSA	Clindamycin	13mg/kg/dose q8h	600mg
<i>S. pyogenes</i> (GAS)	Amoxicillin	30mg/kg/dose q8h	1000mg